Evidence map›Paper›PMID 42907944›Full record

ReviewJournal of anesthesia, analgesia and critical care2026

Pharmacology of vasopressors and inotropes during extracorporeal membrane oxygenation.

Hannah M Brinkman, Jamel P Ortoleva, Abigail G Elliott, Dominic V Pisano, Juan G Ripoll, Nathaniel J Martin, Troy G Seelhammer, Mary A Kraybill, Omar Elmadhoun, Alice Bottussi and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of anesthesia, analgesia and critical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hannah M BrinkmanDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Jamel P OrtolevaDepartment of Anesthesiology, Boston Medical Center, Boston, MA, USA.
Abigail G ElliottDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Dominic V PisanoDepartment of Anesthesiology, Boston Medical Center, Boston, MA, USA.
Juan G RipollDeparment of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
Nathaniel J MartinDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Troy G SeelhammerDeparment of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
Mary A KraybillDepartment of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA.
Omar ElmadhounDeparment of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
Alice BottussiDepartment of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marc LeoneDepartment of Anesthesia and Intensive Care Unit, Nord Hospital, Assistance Publique- Hôpitaux de Marseille (AP-HM), Aix Marseille Université, Marseille, France.
Erica D WittwerDeparment of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
Elena Giovanna BignamiAnesthesiology, Critical Care and Pain Medicine Division, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Jacopo D'Andria UrsoleoDepartment of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. dandria.jacopo@hsr.it.
Patrick M WieruszewskiDepartment of Pharmacy, Mayo Clinic, Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis review aims to provide a concise summary of hemodynamic considerations and the pharmacology and current evidence of vasoactive support, including inotropes and vasopressors, during extracorporeal membrane oxygenation (ECMO) support. MAIN TEXT: Patients requiring ECMO for cardiogenic shock or cardiac arrest have a high mortality rate. Despite advancements in medical and mechanical therapies, optimal use of vasoactive in patients receiving venoarterial ECMO is not well defined. Venoarterial ECMO introduces unique hemodynamic disturbances and considerations for the provision of vasoactive medications. Many different pharmacotherapies with varying inotropic, vasoconstrictive, and vasodilating effects are available and include catecholamine and non-catecholamine agents. Mechanisms and level of evidence vary based on agent, yet distinct characteristics may make certain agents more attractive than others depending on the clinical situation faced during ECMO.

conclusionsA nuanced understanding of receptor pharmacology and ECMO specific considerations is essential to tailor the vasoactive strategy in this unique population.

Indexed as

Extracorporeal life supportExtracorporeal membrane oxygenationInotropePharmacologyShockV-AECMOVasoactiveVasopressor

Identifiers

PMID42907944
PMCPMC13689082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.